Risk factors for esophageal fistula in patients with locally advanced esophageal carcinoma receiving chemoradiotherapy

Background This study aimed to investigate risk factors for esophageal fistula in patients with locally advanced esophageal carcinoma receiving chemoradiotherapy. Subjects and methods The study prospectively enrolled 212 esophageal carcinoma patients undergoing chemoradiotherapy and evaluated 16 clinical parameters. The best cut-off values were determined by receiver operating characteristics curves. Hazard ratios (HR) and 95% confidence intervals (CIs) were calculated by the Cox proportional hazards model. Kaplan–Meier analysis was used to evaluate the cumulative probability. Results In total, 22 patients (10.38%) developed esophageal fistula, of whom 9 experienced fistula during treatment and the other 13 patients developed fistula after chemoradiotherapy. The median time until occurrence was 5.75 months (range 0.6–8 months). In univariate analysis, the evaluated significant factors were Karnofsky performance status, smoking status, esophageal stenosis, T stage, fraction dose, and carcinoembryonic antigen (CEA). In addition, esophageal stenosis (HR=4.089, 95% CI 1.451–11.527, p=0.008), T stage (HR=2.663, 95% CI 1.019–6.960, p=0.046), and CEA (HR=0.309, 95% CI 0.124–0.768, p=0.011) were revealed as risk parameters in further multivariate analysis. Conclusion This is the first prospective study to evaluate factors associated with fistula formation in patients with esophageal carcinoma receiving chemoradiotherapy. More attention should be given to patients with esophageal stenosis, stage T4 disease, and high levels of CEA.

[1]  Baosheng Li,et al.  CYFRA21-1 and CEA are useful markers for predicting the sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma , 2009, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[2]  J. Noh,et al.  High-dose radiation therapy alone by moderate hypofractionation for patients with thoracic esophageal squamous cell carcinoma , 2016, Medicine.

[3]  Y. Nishimura,et al.  Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula. , 2002, International journal of radiation oncology, biology, physics.

[4]  Ping Zhang,et al.  Salvage radiotherapy in patients with local recurrent esophageal cancer after radical radiochemotherapy , 2015, Radiation oncology.

[5]  P. Kupcsulik,et al.  Characteristics of Esophagorespiratory Fistulas Resulting from Esophageal Cancers: A Single-Center Study on 243 Cases in a 20-Year Period , 2009, World Journal of Surgery.

[6]  Jose Pablo Diaz-Jimenez,et al.  Malignant respiratory–digestive fistulas , 2010, Current opinion in pulmonary medicine.

[7]  Wei Zhao,et al.  Prognostic significance of CYFRA21-1, CEA and hemoglobin in patients with esophageal squamous cancer undergoing concurrent chemoradiotherapy. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[8]  Phil Gold,et al.  SPECIFIC CARCINOEMBRYONIC ANTIGENS OF THE HUMAN DIGESTIVE SYSTEM , 1965, The Journal of experimental medicine.

[9]  M. Shinoda,et al.  Risk Factors for Esophageal Fistula Associated With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Cancer , 2016, Medicine.

[10]  Y. Yonemura,et al.  Preoperative Carcinoembryonic Antigen Level Predicts Prognosis in Patients with Pseudomyxoma Peritonei Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy , 2013, World Journal of Surgery.

[11]  H. Fujita A history of surgery for locally-advanced (T4) cancer of the thoracic esophagus in Japan and a personal perspective. , 2013, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.

[12]  A. Jemal,et al.  Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.

[13]  C. Castoro,et al.  Esophageal Cancer Management: Preoperative CA19.9 and CEA Serum Levels May Identify Occult Advanced Adenocarcinoma , 2015, World Journal of Surgery.

[14]  S. Sivaraman,et al.  Radiation-induced aortoesophageal fistula: an unusual case of massive upper gastrointestinal bleeding. , 2002, The Journal of emergency medicine.

[15]  S. Law Chemoradiotherapy - panacea for esophageal cancer? Commentary for 'Chemoradiotherapy of locally advanced esophageal cancer. Long-term follow-up of a prospective randomized trial (RTOG 85-01)' , 1999 .

[16]  T. Kawano,et al.  Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303) , 2015, Cancer science.

[17]  L. Freitag,et al.  Management of malignant esophagotracheal fistulas with airway stenting and double stenting. , 1996, Chest.

[18]  Phil Gold,et al.  DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES , 1965, The Journal of experimental medicine.

[19]  M. Shinoda,et al.  Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). , 2004, Japanese journal of clinical oncology.

[20]  N. Gabrail,et al.  Chemo‐irradiation induced aortoesophageal fistula , 1991, Journal of surgical oncology.

[21]  J. Cooper,et al.  Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. , 1999, JAMA.

[22]  M. Okada,et al.  Role of definitive chemoradiotherapy using docetaxel and 5-fluorouracil in patients with unresectable locally advanced esophageal squamous cell carcinoma: a phase II study. , 2016, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[23]  N. Boku,et al.  Risk factors and clinical courses of chemoradiation-related arterio-esophageal fistula in esophageal cancer patients with clinical invasion of the aorta , 2011, International Journal of Clinical Oncology.